People · Operator
Named in public records as an officer, director or promoter · active 2016–2025 · Healthtech, Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Imperative Care, Inc. | — | Healthtech | Series D+ | $584.7M | $713.0M | 2017 |
| Instylla, Inc. | — | Biotechnology | Series B | $85.5M | $100.3M | 2025 |
| Averna Therapeutics Inc. | — | Pharma | Series C | $85.0M | $805.8M | 2024 |
| Atia Vision, Inc. | — | Biotechnology | Series B | $51.0M | $466.9M | 2018 |
| Tulavi Therapeutics, Inc. | — | Biotechnology | Series A | $14.5M | $17.9M | 2018 |
| Apama Medical, Inc. | — | Healthtech | Series A | $14.3M | $297.4M | 2016 |
| Curamir Therapeutics, Inc. | — | Pharma | Series A | $5.2M | $160.3M | 2019 |
Henry Chen at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Henry Chen on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| FARHAD KHOSRAVI | 4 | 14 |
| Tara Butler | 3 | 12 |
| AMR SALAHIEH | 2 | 10 |
| Amar Sawhney | 2 | 6 |
| Greg Casciaro | 2 | 4 |
| BIHUA CHEN | 1 | 14 |
| Stephen Squinto | 1 | 8 |
| Amarpreet Sawhney | 1 | 8 |
| Dylan Morris | 1 | 8 |
| Michal Silverberg | 1 | 7 |
| Mariam Maghribi | 1 | 6 |
| Andrew Hack | 1 | 5 |
| Hank Plain | 1 | 5 |
| Evan S. Melrose | 1 | 5 |
| STACY ENXING SENG | 1 | 5 |
| Darshana Zaveri | 1 | 5 |
| Steven Cagnetta | 1 | 5 |
| Richard Morris | 1 | 4 |
| Fan Yu | 1 | 4 |
| Daniel Davis | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.